1. ncbi.nlm.nih.gov

    National Center for Biotechnology Information

    https://www.ncbi.nlm.nih.gov › pmc › articles › PMC8597888

    Several antiviral drugs have shown to be effective in reducing progression of COVID-19 disease. ... can significantly reduce COVID-19 hospitalizations and deaths and can help control SARS-CoV-2 transmission. ... Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 ...
    Author:L. Matrajt, E. R. Brown, D. Dimitrov, H. JanesPublished:2021
  2. med.cuhk.edu.hk

    May 20, 2024CU Medicine conducted a retrospective investigation using real-world data to examine the association of Paxlovid (also known as nirmatrelvir-ritonavir) with post-acute sequelae in hospitalised COVID-19 patients, as well as mortality from the disease. The results showed that the risk of post-acute inpatient death (i.e. death occurring 21 days after a positive test result) in COVID-19 patients ...
  3. Was this helpful?
  4. pubmed.ncbi.nlm.nih.gov

    Preliminary studies showed oral antiviral drugs significantly reduce hospitalization or death among mild to severe patients. Moreover, the US FDA has approved four monoclonal antibodies for Covid-19 treatment. Studies suggest that these drugs would reduce the risk of hospitalization or severity of symptoms.
  5. cidrap.umn.edu

    The antiviral drug Paxlovid drove down the risk of COVID-19 hospitalization or death by 44% in a highly vaccinated group of US adults aged 50 and older, suggests a large study published today in the Annals of Internal Medicine.. A team led by Brigham and Women's Hospital researchers studied the risk of hospitalization by 14 days and death by 28 days among 44,551 nonhospitalized COVID-19 ...
  6. meduniwien.ac.at

    Nov 6, 2024The analysis showed that the risk of hospitalisation and premature death was significantly lower in patients aged 60 and over who were treated with nirmatrelvir-ritonavir than in untreated control subjects. "These effects were only found in older patients, however, and not in people under the age of 60,"reports first author Anselm Jorda.
  7. pmc.ncbi.nlm.nih.gov

    Nirmatrelvir-ritonavir is an oral treatment for SARS-CoV-2 infection in patients who are at high risk of developing severe COVID-19 disease. This antiviral has proven to significantly reduce the risk of hospitalization and death compared to no anti-SARS-CoV-2 treatment in this target population.
  8. ncbi.nlm.nih.gov

    National Center for Biotechnology Information

    https://www.ncbi.nlm.nih.gov › pmc › articles › PMC9728013

    Accordingly, two orally applicable drugs, nirmatrelvir/ritonavir and molnupiravir have demonstrated, in two double-blinded randomized controlled trials, that they significantly reduce the risk of hospitalization or death in patients who are unvaccinated and ambulatory with risk factors for severe infection, when given within the first days ...
  9. ncbi.nlm.nih.gov

    National Center for Biotechnology Information

    https://www.ncbi.nlm.nih.gov › pmc › articles › PMC8758150

    On Dec 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use authorisation for Pfizer's COVID-19 antiviral, Paxlovid.Trial results released by the manufacturer indicate that the drug cuts the risk of hospitalisation or death for high-risk patients by 88%, compared with the placebo, if given within 5 days of symptom onset.
  10. pmc.ncbi.nlm.nih.gov

    Some antiviral drugs are statistically and clinically different. In terms of in-hospital mortality, a significantly lower risk of COVID-19 was observed in the study group receiving anti-viral baricitinib compared to the control group receiving placebo. IVM was more effective than placebos in terms of recovery time.
  11. med.cuhk.edu.hk

    Dec 29, 2024Two recent studies conducted by researchers at The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) have provided significant insights into the effectiveness of the oral antiviral drug Paxlovid (also known as nirmatrelvir-ritonavir) on post-acute death and sequelae after COVID-19 infection, as well as its interaction with vaccination status. In the first study ...

    Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX